title: Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention.
abstract: OBJECTIVE
  β-blockers are the standard treatment for myocardial infarction (MI) based on evidence from the pre-thrombolytic era. The aim of this study was to examine the effect of β-blocker treatment in patients with acute MI and preserved systolic function in the era of percutaneous coronary intervention (PCI).
  
  
  METHODS
  We analysed a multicentre registry and identified 3019 patients who presented with acute MI between 2004 and 2009. Patients were treated with PCI, had left ventricular EFs ≥50% according to echocardiograms that were performed during the index PCI, and were alive at the time of discharge. The association between β-blocker use after discharge and mortality (all-cause death and cardiac death) within 3 years was examined.
  
  
  RESULTS
  Patients who were not treated with β-blockers (n=595) showed higher rates of all-cause death and cardiac death compared to patients treated with β-blockers (10.8% vs 5.7%, p<0.001, 7.6% vs 2.6%, p<0001). The multivariate Cox proportional hazards model showed that β-blocker treatment was associated with a significant reduction in all-cause death (adjusted HR 0.633, 95% CI 0.464 to 0.863; p=0.004) and cardiac death (adjusted HR 0.47, 95% CI 0.32 to 0.70; p<0.001). Comparable results were obtained after propensity score matching.
  
  
  CONCLUSIONS
  β-blocker treatment was associated with reduced long term mortality in patients with acute MI and preserved systolic function who received PCI.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, , Seoul, Korea.
authors.forename: Eun Ho
authors.initials: EH
authors.lastname: Choo
authors.forename: Kiyuk
authors.initials: K
authors.lastname: Chang
authors.forename: Youngkeun
authors.initials: Y
authors.lastname: Ahn
authors.forename: Doo Soo
authors.initials: DS
authors.lastname: Jeon
authors.forename: Jong Min
authors.initials: JM
authors.lastname: Lee
authors.forename: Dong Bin
authors.initials: DB
authors.lastname: Kim
authors.forename: Sung-Ho
authors.initials: SH
authors.lastname: Her
authors.forename: Chul Soo
authors.initials: CS
authors.lastname: Park
authors.forename: Hee Yeol
authors.initials: HY
authors.lastname: Kim
authors.forename: Ki-Dong
authors.initials: KD
authors.lastname: Yoo
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Ki-Bae
authors.initials: KB
authors.lastname: Seung
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D012042:Registries; D056910:Republic of Korea / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D013599:Systole; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists